Showing 1 - 6 results of 6 for search 'Murat O. Arcasoy', query time: 0.05s Refine Results
  1. 1
    Non-erythroid effects of erythropoietin

    Non-erythroid effects of erythropoietin by Murat O. Arcasoy

    Published 2010-11-01
    Get full text
    Article
  2. 2
    Immune Thrombocytopenia Associated with Hepatitis B Virus and Autoimmune Hepatitis and Recovery of Platelet Count following Liver Transplantation

    Immune Thrombocytopenia Associated with Hepatitis B Virus and Autoimmune Hepatitis and Recovery of Platelet Count following Liver Transplantation by Chloe Nobuhara, Diana M. Cardona, Murat O. Arcasoy, Carl L. Berg, Andrew S. Barbas

    Published 2021-01-01
    Get full text
    Article
  3. 3
    Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.

    Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. by Matthew E Hardee, Yiting Cao, Ping Fu, Xiaohong Jiang, Yulin Zhao, Zahid N Rabbani, Zeljko Vujaskovic, Mark W Dewhirst, Murat O Arcasoy

    Published 2007-06-01
    Get full text
    Article
  4. 4
    Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

    Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I by Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, Victor Sandor, Hagop Kantarjian

    Published 2015-04-01
    Get full text
    Article
  5. 5
    Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

    Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I by Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson-Viitanen, William Sun, Victor Sandor, Hagop M. Kantarjian

    Published 2013-12-01
    Get full text
    Article
  6. 6
    Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

    Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies by Ruben A. Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard Levy, Andres Siulnik, Vikas Gupta, Mahmudul Khan, John F. DiPersio, Mari McQuitty, John V. Catalano, Deborah S. Hunter, Laurent Knoops, Michael Deininger, Francisco Cervantes, Carole Miller, Alessandro M. Vannucchi, Richard T. Silver, Tiziano Barbui, Moshe Talpaz, Giovanni Barosi, Elliott F. Winton, Estella Mendeson, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, William Sun, Victor Sandor, Hagop M. Kantarjian, Claire Harrison

    Published 2014-02-01
    Get full text
    Article

Search Tools: